Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Xenia F. Gerloff"'
Autor:
Heike Peterziel, Nora Jamaladdin, Dina ElHarouni, Xenia F. Gerloff, Sonja Herter, Petra Fiesel, Yannick Berker, Mirjam Blattner-Johnson, Kathrin Schramm, Barbara C. Jones, David Reuss, Laura Turunen, Aileen Friedenauer, Tim Holland-Letz, Martin Sill, Lena Weiser, Christopher Previti, Gnanaprakash Balasubramanian, Nicolas U. Gerber, Johannes Gojo, Caroline Hutter, Ingrid Øra, Olli Lohi, Antonis Kattamis, Bram de Wilde, Frank Westermann, Stephan Tippelt, Norbert Graf, Michaela Nathrath, Monika Sparber-Sauer, Astrid Sehested, Christof M. Kramm, Uta Dirksen, Olli Kallioniemi, Stefan M. Pfister, Cornelis M. van Tilburg, David T. W. Jones, Jani Saarela, Vilja Pietiäinen, Natalie Jäger, Matthias Schlesner, Annette Kopp-Schneider, Sina Oppermann, Till Milde, Olaf Witt, Ina Oehme
Publikováno v:
npj Precision Oncology, Vol 6, Iss 1, Pp 1-17 (2022)
Abstract The international precision oncology program INFORM enrolls relapsed/refractory pediatric cancer patients for comprehensive molecular analysis. We report a two-year pilot study implementing ex vivo drug sensitivity profiling (DSP) using a li
Externí odkaz:
https://doaj.org/article/d21634f309aa434aa0d7808304d8ec37
Autor:
Charlotte Gatzweiler, Johannes Ridinger, Sonja Herter, Xenia F. Gerloff, Dina ElHarouni, Yannick Berker, Roland Imle, Lukas Schmitt, Sina Kreth, Sabine Stainczyk, Simay Ayhan, Sara Najafi, Damir Krunic, Karen Frese, Benjamin Meder, David Reuss, Petra Fiesel, Kathrin Schramm, Mirjam Blattner-Johnson, David T. W. Jones, Ana Banito, Frank Westermann, Sina Oppermann, Till Milde, Heike Peterziel, Olaf Witt, Ina Oehme
Publikováno v:
Cancers, Vol 14, Iss 3, p 849 (2022)
The survival rate among children with relapsed tumors remains poor, due to tumor heterogeneity, lack of directly actionable tumor drivers and multidrug resistance. Novel personalized medicine approaches tailored to each tumor are urgently needed to i
Externí odkaz:
https://doaj.org/article/cd782fa9988147faa25f5712c6e4facb
Autor:
Michael Müller, Lisa Rösch, Sara Najafi, Charlotte Gatzweiler, Johannes Ridinger, Xenia F. Gerloff, David T. W. Jones, Jochen Baßler, Sina Kreth, Sabine Stainczyk, Karen Frese, Benjamin Meder, Frank Westermann, Till Milde, Heike Peterziel, Olaf Witt, Ina Oehme
Publikováno v:
Cancers, Vol 13, Iss 17, p 4476 (2021)
APR-246 (Eprenetapopt/PRIMA-1Met) is a very potent anti-cancer drug in clinical trials and was initially developed as a p53 refolding agent. As an alternative mode of action, the elevation of reactive oxygen species (ROS) has been proposed. Through a
Externí odkaz:
https://doaj.org/article/4ce7352813a94cf9a0e11429e771f448
Broad-Spectrum HDAC Inhibitors Promote Autophagy through FOXO Transcription Factors in Neuroblastoma
Autor:
Katharina Körholz, Johannes Ridinger, Damir Krunic, Sara Najafi, Xenia F. Gerloff, Karen Frese, Benjamin Meder, Heike Peterziel, Silvia Vega-Rubin-de-Celis, Olaf Witt, Ina Oehme
Publikováno v:
Cells, Vol 10, Iss 5, p 1001 (2021)
Depending on context and tumor stage, deregulation of autophagy can either suppress tumorigenesis or promote chemoresistance and tumor survival. Histone deacetylases (HDACs) can modulate autophagy; however, the exact mechanisms are not fully understo
Externí odkaz:
https://doaj.org/article/87ecc03626b04d9fb7aef1cb74b7d2f5
Autor:
Romain Sigaud, Lisa Rösch, Charlotte Gatzweiler, Julia Benzel, Laura von Soosten, Heike Peterziel, Florian Selt, Sara Najafi, Simay Ayhan, Xenia F Gerloff, Nina Hofmann, Isabel Büdenbender, Lukas Schmitt, Kathrin I Foerster, Jürgen Burhenne, Walter E Haefeli, Andrey Korshunov, Felix Sahm, Cornelis M van Tilburg, David T W Jones, Stefan M Pfister, Deborah Knoerzer, Brent L Kreider, Max Sauter, Kristian W Pajtler, Marc Zuckermann, Ina Oehme, Olaf Witt, Till Milde
Publikováno v:
Neuro-Oncology. 25:566-579
Background Pediatric low-grade gliomas (pLGG) are the most common pediatric central nervous system tumors, with driving alterations typically occurring in the MAPK pathway. The ERK1/2 inhibitor ulixertinib (BVD-523) has shown promising responses in a
Autor:
Romain, Sigaud, Lisa, Rösch, Charlotte, Gatzweiler, Julia, Benzel, Laura, von Soosten, Heike, Peterziel, Florian, Selt, Sara, Najafi, Simay, Ayhan, Xenia F, Gerloff, Nina, Hofmann, Isabel, Büdenbender, Lukas, Schmitt, Kathrin I, Foerster, Jürgen, Burhenne, Walter E, Haefeli, Andrey, Korshunov, Felix, Sahm, Cornelis M, van Tilburg, David T W, Jones, Stefan M, Pfister, Deborah, Knoerzer, Brent L, Kreider, Max, Sauter, Kristian W, Pajtler, Marc, Zuckermann, Ina, Oehme, Olaf, Witt, Till, Milde
Publikováno v:
Neuro-oncology.
Pediatric low-grade gliomas (pLGG) are the most common pediatric central nervous system tumors, with driving alterations typically occurring in the MAPK pathway. The ERK1/2 inhibitor ulixertinib (BVD-523) has shown promising responses in adult patien
Broad-Spectrum HDAC Inhibitors Promote Autophagy through FOXO Transcription Factors in Neuroblastoma
Autor:
Sara Najafi, Johannes Ridinger, Olaf Witt, Katharina Körholz, Karen S. Frese, Benjamin Meder, Heike Peterziel, Damir Krunic, Xenia F Gerloff, Silvia Vega-Rubin-de-Celis, Ina Oehme
Publikováno v:
Cells
Cells, Vol 10, Iss 1001, p 1001 (2021)
Volume 10
Issue 5
Cells, Vol 10, Iss 1001, p 1001 (2021)
Volume 10
Issue 5
Depending on context and tumor stage, deregulation of autophagy can either suppress tumorigenesis or promote chemoresistance and tumor survival. Histone deacetylases (HDACs) can modulate autophagy
however, the exact mechanisms are not fully unde
however, the exact mechanisms are not fully unde
Autor:
Olaf Witt, Xenia F. Gerloff, Sina Kreth, David T.W. Jones, Sara Najafi, Karen S. Frese, Michael W. Müller, Frank Westermann, Till Milde, Sabine A. Stainczyk, Johannes Ridinger, Charlotte Gatzweiler, Jochen Baßler, Heike Peterziel, Lisa Rösch, Benjamin Meder, Ina Oehme
Publikováno v:
Cancers; Volume 13; Issue 17; Pages: 4476
Cancers, Vol 13, Iss 4476, p 4476 (2021)
Cancers
Cancers, Vol 13, Iss 4476, p 4476 (2021)
Cancers
Simple Summary Preclinical analyses identified APR-246 as a potent treatment option for neuroblastoma. However, a specific mode of action, sufficient biomarkers and promising combination partners are still missing. Here, we analyze the susceptibiliti